Startup profile · funding coverage
Arda Therapeutics funding, valuation and investors
Targeted cell-depletion therapies for chronic diseases using oncology modalities outside cancer.
Keep track of Arda Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$43M · 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$43M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · South San Francisco, California
Investors in latest funding
Other: Andreessen Horowitz
Overview
Arda Therapeutics develops targeted cell-depletion medicines that use antibody-drug conjugate and T-cell engager modalities proven in oncology to treat chronic diseases like fibrosis and immunology conditions. The company's single-cell discovery platform identifies pathogenic cell types to deplete rather than broadly suppress immune function.
Why Arda Therapeutics is interesting
Applying ADC and T-cell engager approaches to fibrosis and immunology — single-cell biology engine to selectively remove pathogenic cell populations.
Product & use cases
Arda Therapeutics develops targeted cell-depletion medicines that use antibody-drug conjugate and T-cell engager modalities proven in oncology to treat chronic diseases like fibrosis and immunology conditions.
- Enterprise platform deployment for core workflows
Key facts
- Series A (2024): $43M led by a16z with Two Sigma Ventures, GV, Eli Lilly (Business Wire)
- Seed (2022): a16z Bio + Health led at inception (a16z announcement)
- Thesis: ADC/TCE cell depletion for fibrosis and immunology beyond oncology (Arda site)
- Co-investors not in VCT directory: GV (Google Ventures), Eli Lilly
Funding history (newest first)
Series A
2024 $43MSource: Series A (2024): $43M led by a16z with Two Sigma Ventures, GV, Eli Lilly (Business Wire)
Seed
2022Source: Seed (2022): a16z Bio + Health led at inception (a16z announcement)
Investors in our directory
Funds linked from Arda Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Applying ADC and T-cell engager approaches to fibrosis and immunology — single-cell biology engine to selectively remove pathogenic cell populations.
Arda Therapeutics competes in biotech-life-sciences. Incumbents have distribution; startup edge depends on product depth and buyer references. See competitors for specific tradeoffs — no invented market share claims.
-
Veeva incumbent
Life sciences cloud incumbent.
-
Dotmatics adjacent
R&D informatics.
Notable stories
- Series A (2024): $43M led by a16z with Two Sigma Ventures, GV, Eli Lilly (Business Wire)
- Seed (2022): a16z Bio + Health led at inception (a16z announcement)
Industries
Related funding articles
Venture Capital Tracker pieces that cover Arda Therapeutics's financing or category context.
FAQs about Arda Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.